Corvus Pharma: Soquelitinib Advancing Towards Initial Enrollment for Registrational Phase 3 Clinical Trial for PTCL and Randomized Phase 1 Clinical Trial for Atopic Dermatitis >CRVS
Corvus Pharma: Soquelitinib Advancing Towards Initial Enrollment for Registrational Phase 3 Clinical Trial for PTCL and Randomized Phase 1 Clinical Trial for Atopic Dermatitis >CRVS
Corvus Pharma：索克利替尼即将进行PTCL的注册性3期临床试验和特应性皮炎的随机1期临床试验 >CRVS 的初始入组
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册